Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 4
2017 2
2018 2
2020 3
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Uncommon Anal Neoplasms.
Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, Segelov E. Roy AC, et al. Surg Oncol Clin N Am. 2017 Jan;26(1):143-161. doi: 10.1016/j.soc.2016.07.009. Surg Oncol Clin N Am. 2017. PMID: 27889033 Review.
Targeted therapy for metastatic colorectal cancer.
Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J. Price TJ, et al. Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006. doi: 10.1080/14737140.2018.1502664. Epub 2018 Aug 3. Expert Rev Anticancer Ther. 2018. PMID: 30019590 Review.
Global Oncology Authorship and Readership Patterns.
Bourlon MT, Jiménez Franco B, Castro-Alonso FJ, Bourlon C, Matar CF, Gunn E, Ginsburg O, Lopes G, Segelov E. Bourlon MT, et al. JCO Glob Oncol. 2022 Mar;8:e2100299. doi: 10.1200/GO.21.00299. JCO Glob Oncol. 2022. PMID: 35258989 Free PMC article.
Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Tang M, et al. Expert Rev Anticancer Ther. 2018 Apr;18(4):339-349. doi: 10.1080/14737140.2018.1444481. Epub 2018 Mar 1. Expert Rev Anticancer Ther. 2018. PMID: 29478352 Review.
Current opinion on optimal treatment for colorectal cancer.
Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, Shapiro JD. Price TJ, et al. Expert Rev Anticancer Ther. 2013 May;13(5):597-611. doi: 10.1586/era.13.37. Expert Rev Anticancer Ther. 2013. PMID: 23617351 Review.
Advances in adjuvant therapy have been limited to the addition of oxaliplatin and the substitution of oral fluoropyrimidine (e.g., capecitabine) for intravenous 5-fluorouracil with no evidence for improved outcome with biological agents. ...
Advances in adjuvant therapy have been limited to the addition of oxaliplatin and the substitution of oral fluoropyrimidine (e.g., ca …
Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.
Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Segelov E, et al. Expert Rev Anticancer Ther. 2017 Oct;17(10):951-964. doi: 10.1080/14737140.2017.1369882. Epub 2017 Aug 28. Expert Rev Anticancer Ther. 2017. PMID: 28817982 Review.
Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial.
Segelov E, Prenen H, Day D, Macintyre CR, Foo EMJ, Ali R, Wang Q, Wei X, Lopes GL Jr, Ding K, Chen G, Chia JWK, Toh HC; ASCOLT Investigators. Segelov E, et al. JCO Glob Oncol. 2020 Apr;6:585-588. doi: 10.1200/GO.20.00072. JCO Glob Oncol. 2020. PMID: 32293940 Free PMC article. No abstract available.
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
Jackson CGCA, Hung T, Segelov E, Barlow P, Prenen H, McLaren B, Hung NA, Clarke K, Chao TY, Dai MS, Yeh HT, Cutler DL, Kramer D, He J, Zhi J, Chan WK, Kwan R, Deva S. Jackson CGCA, et al. Br J Clin Pharmacol. 2021 Dec;87(12):4670-4680. doi: 10.1111/bcp.14886. Epub 2021 Jun 18. Br J Clin Pharmacol. 2021. PMID: 33960504 Free article. Clinical Trial.
G3 treatment-emergent adverse events occurred in seven (18%) pts with oPac+E and two (5%) with IVP. Seventy-five per cent of patients preferred oPac+E over IVP. ...With further study, oPac+E could be an alternative to IVP....
G3 treatment-emergent adverse events occurred in seven (18%) pts with oPac+E and two (5%) with IVP. Seventy-five per cent of patients …
15 results